WallStSmart

Curanex Pharmaceuticals Inc Common Stock (CURX)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CURX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

CURX

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 3/9

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CURX1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CURX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.99M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CURX

The strongest argument for CURX centers on Debt/Equity.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : CURX

The primary concerns for CURX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

CURX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

INSM is growing revenue faster at 1.5% — sustainability is the question.

CURX generates stronger free cash flow (-9M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Curanex Pharmaceuticals Inc Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. The company is headquartered in Jericho, New York.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?